ALK Gene Rearrangements: A New Therapeutic Target in a Molecularly Defined Subset of Non-small Cell Lung Cancer Benjamin Solomon, MBBS, PhD, Marileila.

Slides:

Advertisements

Similar presentations

Frances A Shepherd, MD, Rafael Rosell, MD Journal of Thoracic Oncology

Advertisements

Naomi Fujioka, MD, Christopher A. French, MD, Michael J

Is Cytology Reliable for Epidermal Growth Factor Receptor Gene Evaluation in Non- small Cell Lung Cancer? Cecilia Bozzetti, PhD, Marcello Tiseo, MD, Costanza.

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

Volume 52, Issue 1, Pages (July 2007)

Tolerable and Effective Combination of Full-Dose Crizotinib and Osimertinib Targeting MET Amplification Sequentially Emerging after T790M Positivity in.

Detection of ALK Gene Rearrangement in Non-small Cell Lung Cancer: A Comparison of Fluorescence In Situ Hybridization and Chromogenic In Situ Hybridization.

EGFR Array: Uses in the Detection of Plasma EGFR Mutations in Non–Small Cell Lung Cancer Patients Irene Yam, BSc, David Chi-Leung Lam, MBBS, PhD, Kaimin.

Detection of Rearrangements and Transcriptional Up-Regulation of ALK in FFPE Lung Cancer Specimens Using a Novel, Sensitive, Quantitative Reverse Transcription.

Next-Generation Sequencing Identifies and Immunohistochemistry Confirms a Novel Crizotinib-Sensitive ALK Rearrangement in a Patient with Metastatic Non–Small-Cell.

ALK FISH and IHC: You Cannot Have One without the Other

EGFR and HER2 Genomic Gain in Recurrent Non-small Cell Lung Cancer After Surgery: Impact on Outcome to Treatment with Gefitinib and Association with EGFR.

Heterogeneity of Anaplastic Lymphoma Kinase Gene Rearrangement in Non–Small-Cell Lung Carcinomas: A Comparative Study Between Small Biopsy and Excision.

Characterization of Fibroblast Growth Factor Receptor 1 in Small-Cell Lung Cancer Anish Thomas, MD, Jih-Hsiang Lee, MD, Zied Abdullaev, PhD, Kang-Seo.

FISH Analysis of Crizotinib Target Genes ROS1/ALK/MET in Malignant Mesothelioma Sandra Salvi, PhD, Serena Varesano, PhD, Simona Boccardo, PhD, Jean Louis.

Clinicopathologic Analysis of ROS1-Rearranged Non–Small-Cell Lung Cancer and Proposal of a Diagnostic Algorithm Heounjeong Go, MD, PhD, Dong-Wan Kim,

Response to Crizotinib Rechallenge after Initial Progression and Intervening Chemotherapy in ALK Lung Cancer Eiko Theodora Browning, MD, Andrew James.

Responses to Crizotinib Can Occur in High-Level MET-Amplified Non–Small Cell Lung Cancer Independent of MET Exon 14 Alterations Rafael Caparica, MD,

Increased ALK Gene Copy Number and Amplification are Frequent in Non-small Cell Lung Cancer Marta Salido, MSc, Lara Pijuan, MD, PhD, Luz Martínez-Avilés,

Bob T. Li, M. B. B. S. , MPH, Dara S. Ross, MD, Dara L

Electronic Updates for JTO Readers

MET and EGFR Mutations Identified in ALK-Rearranged Pulmonary Adenocarcinoma: Molecular Analysis of 25 ALK-Positive Cases Jennifer M. Boland, MD, Jin.

Bright-Field Dual-Color Chromogenic In Situ Hybridization for Diagnosing Echinoderm Microtubule-Associated Protein-Like 4-Anaplastic Lymphoma Kinase-Positive.

Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,

A Long-Term Spinal Intramedullary Response to Ceritinib in ALK Rearranged Non– Small-Cell Lung Cancer Josette Biya, MD, Caroline Caramella, MD, Colin.

Comprehensive Hybrid Capture–Based Next-Generation Sequencing Identifies a Double ALK Gene Fusion in a Patient Previously Identified to Be False-Negative.

ALK and NRG1 Fusions Coexist in a Patient with Signet Ring Cell Lung Adenocarcinoma Lucia Anna Muscarella, PhD, Domenico Trombetta, PhD, Federico Pio.

A Case of Squamous Cell Carcinoma Harboring an EML4-ALK Rearrangement that Was Unsuccessfully Treated with the ALK Inhibitor Alectinib Akihiro Tamiya,

Dual IHC and FISH Testing for ALK Gene Rearrangement in Lung Adenocarcinomas in a Routine Practice: A French Study Anne McLeer-Florin, PhD, Denis Moro-Sibilot,

Combined Use of ALK Immunohistochemistry and FISH for Optimal Detection of ALK- Rearranged Lung Adenocarcinomas Lynette M. Sholl, MD, Stanislawa Weremowicz,

Kelsie L. Thu, BSc, Raj Chari, PhD, William W

ALK/EML4 Fusion Gene May Be Found in Pure Squamous Carcinoma of the Lung Anna Caliò, MD, Alessia Nottegar, MD, Eliana Gilioli, MD, Emilio Bria, MD, Sara.

ALK Rearrangement Detected in a Focus of Pulmonary Atypical Adenomatous Hyperplasia Filippo Lococo, MD, Alessandra Bisagni, MD, Maria Cecilia Mengoli,

Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.

Searching for ROS1 Rearrangements in Lung Cancer by Fluorescent In Situ Hybridization: The Importance of Probe Design Arnaud Uguen, MD, Pascale Marcorelles,

A Novel EML4-ALK Variant: Exon 6 of EML4 Fused to Exon 19 of ALK

Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer Masahiko Harada,

Chromosomal Abnormalities in Non-Small Cell Lung Carcinomas and in Bronchial Epithelia of High-Risk Smokers Detected by Multi-Target Interphase Fluorescence.

Assessment of ALK Status by FISH on 1000 Spanish Non-Small Cell Lung Cancer Patients Joana Vidal, MD, Sergi Clavé, MSc, Silvia de Muga, PhD, Iria González,

Role of Chromosome 3q Amplification in Lung Cancer

High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer Heounjeong Go, MD, Yoon Kyung Jeon, MD, PhD, Hyo Jin.

Rapid and Dramatic Radiographic and Clinical Response to an ALK Inhibitor (Crizotinib, PF ) in an ALK Translocation-Positive Patient with Non-small.

A Comprehensive Analysis of p16 Expression, Gene Status, and Promoter Hypermethylation In Surgically Resected Non-small Cell Lung Carcinomas William.

Response to Crizotinib Observed in Lung Adenocarcinoma with MET Copy Number Gain but without a High-Level MET/CEP7 Ratio, MET Overexpression, or Exon.

Erratum Journal of Thoracic Oncology

NUT Rearrangement is Uncommon in Human Thymic Epithelial Tumors

Arnaud Uguen, MD, PhD Journal of Thoracic Oncology

High MET Receptor Expression But Not Gene Amplification in ALK 2p23 Rearrangement Positive Non–Small-Cell Lung Cancer Yan Feng, MD, Eugen C. Minca, MD,

A Novel Mechanism of EML4-ALK Rearrangement Mediated by Chromothripsis in a Patient-Derived Cell Line Tatsushi Kodama, MS, Noriko Motoi, MD, PhD, Hironori.

Loss of p16INK4A Expression and Homozygous CDKN2A Deletion Are Associated with Worse Outcome and Younger Age in Thymic Carcinomas Scott W. Aesif, MD,

Detection of ALK-Positive Non–Small-Cell Lung Cancers on Cytological Specimens: High Accuracy of Immunocytochemistry with the 5A4 Clone Spasenija Savic,

Mitotic Inhibitors Journal of Thoracic Oncology

A Primer on Health Economic Evaluations in Thoracic Oncology

Expanded Circulating Tumor Cells from a Patient with ALK-Positive Lung Cancer Present with EML4-ALK Rearrangement Along with Resistance Mutation and Enable.

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

Lung Adenocarcinoma with Concurrent Exon 19 EGFR Mutation and ALK Rearrangement Responding to Erlotinib Sanjay Popat, MRCP, PhD, Alexandra Vieira de.

Atypical Negative ALK Break-Apart FISH Harboring a Crizotinib-Responsive ALK Rearrangement in Non–Small-Cell Lung Cancer Shengxiang Ren, MD, PhD, Fred.

Benjamin Solomon, MBBS, PhD, Richard B. Pearson, PhD

Toni-Maree Rogers, BMLS, Prudence A

Immunohistochemistry is a Reliable Screening Tool for Identification of ALK Rearrangement in Non–Small-Cell Lung Carcinoma and is Antibody Dependent

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

Genetic Changes in Squamous Cell Lung Cancer: A Review

Clinical Implications of Variant ALK FISH Rearrangement Patterns

Ethnic Differences in the Management of Lung Cancer in New Zealand

Fluorescence In Situ Hybridization Identifies Cryptic t(16;16)(p13;q22) Masked By del(16)(q22) in a Case of AML-M4 Eo Shakil H. Merchant, Skip Haines,

Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed D.

Christina S. Baik, MD, MPH, Marc C. Chamberlain, MD, Laura Q. Chow, MD

FGFR1 Amplification in Squamous Cell Carcinoma of The Lung

Waxing and Waning of MET Amplification in EGFR-Mutated NSCLC in Response to the Presence and Absence of Erlotinib Selection Pressure Joel P. Womack,

A Review of First-Line Treatment for Small-cell Lung Cancer

Presentation transcript:

ALK Gene Rearrangements: A New Therapeutic Target in a Molecularly Defined Subset of Non-small Cell Lung Cancer Benjamin Solomon, MBBS, PhD, Marileila Varella-Garcia, PhD, D Ross Camidge, MD, PhD Journal of Thoracic Oncology Volume 4, Issue 12, Pages 1450-1454 (December 2009) DOI: 10.1097/JTO.0b013e3181c4dedb Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 A, Chromosome 2 idiogram showing location and design of the dual-color ALK break-apart fluorescence in situ hybridization (FISH) probe that includes DNA contigs adjacent to the ALK gene, the 3′ contig is labeled with red fluorochromes and the 5′ is labeled with green fluorochromes. B, Non-small cell lung cancer (NSCLC) specimen showing fused red/green signals representing normal copies of the ALK (yellow arrows) and single red and green signals (red and green arrows) indicating that chromosomal break occurred between the 3′ and the 5′ contigs. Journal of Thoracic Oncology 2009 4, 1450-1454DOI: (10.1097/JTO.0b013e3181c4dedb) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions